Trial Search Results

Value of Mifepristone in Cervical Preparation Prior to Dilation and Evacuation 19-24 Weeks

A common practice for preparation for surgical abortion after 19 weeks gestation is the placement of multiple sets of osmostic dilators 1-2 days prior to the procedure. The investigators aim to study the addition of mifepristone as an adjunct to cervical dilation prior to abortion between 19-24 weeks gestation, and its potential to minimize the number of painful procedures and time in clinic (or away from work/home) that multiple sets of dilators can require. The investigators hypothesize that one set of dilators with mifepristone will result in similar procedure times and decreased "total" time as two sets of dilators.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Santa Clara Valley Medical Center

Stanford Investigator(s):


  • Drug: Mifepristone
  • Other: Hygroscopic cervical dilators
  • Drug: Misoprostol
  • Drug: Intra-amniotic digoxin




Inclusion Criteria:

   - >18 years old

   - Viable, Singleton pregnancy

   - Voluntarily seeking abortion between 19 and 24wks gestation

   - Able to give informed consent and comply with study protocol

   - Fluent in English or Spanish

Exclusion Criteria:

   - Allergy to misoprostol or mifepristone

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kate A Shaw, MD